Introduction {#s1}
============

Since the discovery that monocytes, cultured with GM-CSF and IL-4, differentiate into dendritic cells (DC) ([@B1]), the idea to use *ex vivo* generated DC to vaccinate cancer patients against tumor antigens has been largely explored ([@B2], [@B3]). Many different protocols have been developed for DC differentiation and/or maturation ([@B4]), but there is still a strong need to characterize the relationship between *ex vivo* derived DC and the several *in vivo* circulating DC subsets for which many information are now available in terms of phenotype and functionality ([@B5]). Over the last 25 years, hundreds of clinical trials have been performed mostly without showing consistent clinical responses, despite some encouraging results, especially in recent years ([@B6]--[@B8]). The vast majority of these studies have used mature IL-4-conditioned-DC loaded *ex vivo* with tumor antigens. However, antigen selection has represented one of the major limitations of DC vaccines and it is now widely accepted that broad patient-specific antigen repertoire, using patient tumor lysate or mutanome-derived peptides, represents the most promising DC antigen source ([@B7]--[@B10]).

An alternative to *ex vivo* antigen loading is represented by the so-called *in situ* vaccination. *In situ* vaccination aims at stimulating DC in the tumor to capture and process antigens released by the tumor and present them to immune cells upon migration to draining lymph node. This approach is receiving renewed interest because of the necessity to expand the antigenic repertoire of T cell responses in the checkpoint blockade therapy era ([@B11]--[@B16]). Several approaches are being evaluated in early trials, mostly using DC activators directly inoculated within the tumor ([@B13], [@B16]). However, given the low number of pre-existing DC at tumor site, combination therapy with stimulator of hematopoietic differentiation of DC, such as Flt3L, seems to be required for efficient DC activation ([@B17]--[@B19]).

One way to overcome low intratumoral DC number and ensure a better control of DC phenotype is represented by intratumoral inoculation of *ex vivo* generated DC (*it*DC) aimed at an *in situ* vaccination. First attempts of *it*DC date 20 years back ([@B20]--[@B22]). Since the initial studies, many promising observations were collected on feasibility and efficacy of *it*DC ([@B23]--[@B28]), even though they did not get under the spot into the mainstream DC vaccine field. However, recent clinical results ([@B29]--[@B31]), together with increased interest in *in situ* vaccination to enforce current immunotherapies, highlight *it*DC as a powerful approach that can be rapidly implemented in current checkpoint blockade therapies. In this review, we will present the main results collected in pre-clinical and clinical use of intratumoral delivery of DC and discuss their potential use in combination with current immunotherapy.

Intratumor Injection of DC: a Platform for Endogenous Vaccination {#s2}
=================================================================

As professional antigen processing cells, DCs are characterized by the ability to internalize, process and present antigens and potently interact with T cells, thus inducing their activation ([@B32]). However, tumors develop several "escape mechanisms" to exclude or reduce immune recognition of tumor-associated antigens, including DC exclusion from tumor microenvironment ([@B33]) and inhibition of DC activity ([@B34]). Within such an immunosuppressive environment, the injection of *ex vivo* cultured DC represents a valuable approach to overcome some tumor escape mechanisms, process antigens released in necrotic or apoptotic tumor mileu and activate immune response against tumor-associated antigens ([@B35]). *it*DC can be potentially applied to almost any tumor type: the only pre-requisite is the possibility to directly inoculate DC in the tumor. In fact, as summarized in [Table 1](#T1){ref-type="table"}, *it*DC trials have been performed against pancreas ([@B27], [@B38], [@B44]), liver ([@B27], [@B37]), colorectal ([@B27]), prostate ([@B39]), esophagus ([@B40]), brain ([@B28]), skin ([@B26], [@B42]), lung ([@B31], [@B35]), bile duct ([@B27], [@B35]), breast, ovarian, bladder, neuroendocrine ([@B35]), renal ([@B43]), and hematological tumors ([@B29], [@B30]), and soft tissue sarcoma ([@B41]). With the exception of melanoma (which is clearly accessible), the inoculation of DC was guided by ultrasound, computed tomography scan, or endoscopic ultrasound. Only in the setting of a brain tumor was an intraventricular catheter used ([@B28]).

###### 

Major clinical trials testing *it*DC.

  **DC type**               **Maturation status**   **Clinical setting**                                          **Tumor pre-conditioning**                            **Major findings**                                                                                                                        **References**
  ------------------------- ----------------------- ------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------
  IL4-DC                    Immature                Metastatic melanoma and breast carcinoma                      --                                                    Regressing lesions showed lymphocytes infiltration and reactivity against heat shock proteins                                             ([@B22])
  IL-12 transduced IL4-DC   Immature and mature     Advanced metastatic digestive carcinomas                      --                                                    IL8 retains DC at tumor site                                                                                                              ([@B27], [@B36])
  IL4-DC                    Immature                Refractory hepatoma                                           Radiotherapy                                          Systemic antitumor immune response, NK cytotoxicity                                                                                       ([@B37])
  IL4-DC                    Immature                Glioma                                                        --                                                    Increased overall survival in patients receiving *it*DC vs. intra dermal DC                                                               ([@B28])
  IL4-DC                    Immature                Melanoma                                                      ±Hyperthermia                                         Systemic antitumor immune response, enhanced by local hyperthermia                                                                        ([@B26])
  IL4-DC                    Mature                  Inoperable pancreatic cancer                                  Gemcitabine same day                                  Systemic antitumor immune response and clinical response in combination with lymphokine activated killer cells stimulated with anti-CD3   ([@B38])
  IL4-DC                    Immature                Prostate                                                      Radiotherapy, hormone therapy                         Treatment feasibility, T cells infiltration at tumor site (limited), systemic antitumor immune response (limited)                         ([@B39])
  IL4-DC                    Mature                  Esophageal cancer                                             Chemotherapy                                          DC are retained at tumor site                                                                                                             ([@B40])
  IL4-DC                    Immature                Soft tissue sarcoma                                           Radiotherapy                                          T cells infiltration at tumor site correlated with antitumor immune response,                                                             ([@B41])
  IL4-DC                    Immature                Follicular lymphoma                                           Rituximab and radiotherapy. (GM-CSF given same day)   Systemic antitumor immune response correlated with clinical response                                                                      ([@B29])
  IFN-DC                    Partially mature        Melanoma                                                      Chemotherapy                                          Systemic antitumor immune response                                                                                                        ([@B42])
  Allogeneic IL4-DC         Mature                  Metastatic renal cell carcinoma                               --                                                    Inflammation at tumor site                                                                                                                ([@B43])
  CCL21-transduced IL4-DC   Immature                Non-small cells lung cancer                                   --                                                    Systemic antitumor immune response, T cells infiltration and increased PD1 expression at tumor site                                       ([@B31])
  GM-CSF DC                 Partially mature        Unrespectable, locally advanced, or metastatic solid tumors   --                                                    Increased production of specific cytokines by DC correlated with clinical efficacy                                                        ([@B35])
  IFN-DC                    Partially mature        Follicular lymphoma                                           Rituximab                                             Systemic antitumor immune response; abscopal effect                                                                                       ([@B30])

Even though basal tumor apoptosis/necrosis can be exploited ([@B27], [@B35], [@B44]), *it*DC vaccination strongly benefits from tumor pre-treatment with death-inducing agents, because of the increased release of tumor antigens ([Figure 1A](#F1){ref-type="fig"}) ([@B24], [@B26]). Among the pre-conditioning regimens used, the ones causing immunogenic cell death are clearly preferred, because they couple the release of tumor antigens with DC activating signals ([@B45]--[@B47]). However, as shown by Teitz-Tennenbaum, radiotherapy (RT), inducing calreticulin exposure and other activating signals ([@B48], [@B49]), stimulates DC processing ability, homing to lymph node, and their ability to stimulate T cells even when RT was not inducing tumor cell death ([@B50]). This point indicates that *it*DC can strongly benefit, not only from tumor pre-conditioning with immunogenic cell death treatments, but also with regimens that simply increase immunogenicity of tumors, thus enlarging the range of possible agents that can be used.

![Intratumor inoculation of DC: the importance of preparing tumor microenvironment and its multiple ways of action. **(A)** In the absence of any treatment, tumors are characterized by low levels of basal apoptotic/necrotic cells and an immunosuppressive microenvironment. Within this setting, *it*DC might become tolerogenic, thus increasing tumor immunosuppressive features and eventually causing a detrimental effect. Tumor preconditioning with immunogenic cell death agents, instead, can enhance tumor cells apoptosis, resulting in increased release of tumor-associated antigens and immune activating signals. In this scenario, intratumor inoculated DC sense proinflammatory and immune activating signals, process tumor antigens, and activate antitumor response. **(B)** *it*DC can activate immune response by acting on several mechanisms. After loading tumor released antigens, mature DC migrate to draining lymph node where they interact with T cells and lead to increased clonality and richness of antitumor T cell responses. The DC interaction with intratumor NK cells can activate their cytotoxic activity, which in turn can activate a positive feedback on DC themselves by boosting their maturation, their infiltration and favoring DC/CD4^+^ T cell interactions. *it*DC can also increase infiltration of T cells by secreting chemokines and exert direct cytotoxic effect, resulting in increased tumor cell death and, more importantly, increased release of tumor antigens. The figure was made using the Servier Medical ART set by Servier.](fimmu-10-02303-g0001){#F1}

Among the several pre-conditioning regimens, RT represents the broadest applicable one considering also the ease of adding *it*DC into already well-established RT regimens ([@B24], [@B37], [@B41]). However, clinical trials have also been performed using local hyperthermia ([@B26]), systemic chemotherapy ([@B40]), and tumor-targeting monoclonal antibodies ([@B29], [@B30]) ([Table 1](#T1){ref-type="table"}). While an ideal pre-condition approach should be tailored to tumor type, the use of tumor-targeting monoclonal antibodies raises some fascinating advantages and synergies. First, considering that DC are endowed with antibody-dependent cell-mediated cytotoxicity ([@B51]), the two treatments could directly synergize. In fact, we have shown that direct cytotoxic activity of DC against the lymphoma cell line Karpas-422 was increased after rituximab pre-treatment ([@B30]). Second, it has been shown that, for a successful monoclonal therapy, an NK-DC crosstalk needs to be mounted, where NK cell activation leads to increased cross-presentation and maturation of DC, thus resulting in antitumor T cell activation ([@B52], [@B53]). Therefore, *it*DC might boost such crosstalk, leading to increased NK cell activity and stronger adaptive antitumor immune responses. Third, combining monoclonal antibody with *it*DC can potentially lead to *in situ* vaccination targeted against clinically relevant, rare cells within the tumor, such as cancer stem cells. In fact, even though monoclonal antibodies recognizing cancer stem cells have not yet shown promising results ([@B54]), the possibility to directly target CSC with monoclonal antibodies, in combination with *it*DC to activate T cell immunity against CSC, may hold great promises and deserves future testing.

*it*DC, a 360-Degree Immunotherapy
----------------------------------

Even though *it*DC based therapy is principally aimed at direct *in situ* vaccination, several complementary immunotherapy effects can also result ([Figure 1B](#F1){ref-type="fig"}). As clearly shown by pre-clinical studies on *it*DC, NK cells can be directly targeted and activated by *it*DC ([@B55], [@B56]). In fact, depletion of NK cells led to impaired efficacy of *it*DC. This is not surprising in light of the tight crosstalk existing between DC and NK cells ([@B57], [@B58]). On one side, DC can potently activate NK cell cytotoxicity against tumor cells through secreted cytokines and cell-to-cell contact ([@B59], [@B60]). This, in turn, stimulates NK cells to secrete CCL5, XCL1, and Flt3L in the tumor ([@B61], [@B62]), thus promoting natural DC infiltration and additional cross-priming of tumor-associated antigen ([@B63]). On the other side, NK cells can strongly enhance DC maturation and IL-12 production, stimulate CD4 T cell response and, through IFN-γ, help DC-driven Th1 polarization ([@B64], [@B65]). In line with this crosstalk, it has been observed that high levels of NK cells after DC vaccination correlated with clinical response in acute myeloid leukemia ([@B66]) and advanced hepatoma patients ([@B37]).

Another complementary effect of *it*DC that should be taken into account is the ability of DC (especially upon maturation) to secrete several chemokines that can favor the infiltration of T cells and endogenous DC in the tumor microenvironment. This possibility has been recently tested in renal cell carcinoma by injecting allogeneic DC, therefore, excluding any direct vaccination effect but rather potentiating inflammatory-related signals due to cell allogeneity ([@B43]). Notably, the authors observed a high level of T cell infiltration and induction of tumor specific T cell responses in three out of 11 evaluable patients. Even more interestingly, despite clinical responses not being registered, an unexpected response consisting in high infiltration of T cells was observed in patients subsequently treated with tyrosine kinase inhibitors, thus suggesting a synergistic effect of the allo-*it*DC with tyrosine kinase inhibitors, possibly mediated by their effect against Treg and MDSC ([@B43], [@B67]). This approach has been additionally tested in advanced hepatocellular carcinoma patients where induction of tumor-specific immune activation in a substantial number of patients was observed ([@B68]). Alternative to the use of allogeneic cells, another approach to boost *it*DC ability to inflame the tumor and/or stimulate immune cells has been tested by genetically modifying DC for constitutive expression of activating factors. DC transduced for the expression of IL-7, IL-12, IL-15, IFN-α, and CCL21 have all been tested in pre-clinical models of *it*DC showing encouraging results ([@B20], [@B21], [@B25], [@B55], [@B69], [@B70]), even though clinical experience with IL-12 transduced DC showed limited success ([@B27], [@B36]).

Lastly, despite being usually neglected, DC are also characterized by direct tumoricidal activity, which, in the context of *it*DC, might result in additional tumor cell death and more importantly in increased release of tumor antigens and damage associated molecular patterns, thus potentiating immune reactivation. In fact, *ex vivo* generated DC, circulating conventional DC and plasmacytoid DC exert direct cytotoxicity against tumor cells ([@B51]). This ability has been demonstrated against a large variety of cancer cell lines and can be mediated by both cell-to-cell signals and secreted factors. While TRAIL is the major signal by which DC exert their tumoricidal activity ([@B71]), TNFα, FAS-L, caspase-8, IFN-γ, and Granzyme B can also play a role ([@B51]).

The Ideal DC Phenotype for *it*DC Immunotherapy: Lessons Learned
----------------------------------------------------------------

Conversely to the classical antigen-loaded DC vaccination approach, for which many different protocols for DC differentiation and maturation have been developed and compared ([@B4], [@B72], [@B73]), minimal discussion has been raised regarding the phenotype of DC to be used for intratumoral inoculation. Initial studies focused on the use of immature DC to take advantage of enhanced phagocytic and antigen processing ability of these cells over the mature counterparts ([@B21], [@B25], [@B74]). However, in absence of strong DC activating stimuli (i.e., when tumor pre-conditioning is not performed or not inducing strong immunogenic cell death), immature DC can have a detrimental effect exerting more immunosuppressive rather than immunostimulatory activity ([@B75]--[@B78]). Therefore, a semi-mature phenotype may be preferable to couple phagocytic activity with the predefined immunostimulatory mature phenotype ([@B35]). However, additional immunotherapy effects of *it*DC (see above) should also be taken into account.

While other protocols to generate semi-mature DC have been developed ([@B79], [@B80]), we opted for DC differentiated in the presence of IFN-α instead of IL-4 ([@B30], [@B42]). These cells (named as IFN-DC) have been discovered by our group almost 20 years ago and are characterized by a partially mature phenotype and are endowed with a high migratory behavior and immunostimulatory ability ([@B81]--[@B83]). They have been shown to be more efficient than conventional IL-4-DC in internalizing tumor antigens and in the cross-priming of CD8^+^ T cells, thus promoting anti-tumor immune responses ([@B84], [@B85]). Moreover, it has been shown that IFN-DC can promote efficient NK cell activation, increase expression of cytotoxicity receptors, and stimulate extensive IFN-γ production by NK cells ([@B86]). Interestingly, in two different clinical trials, we observed induction of long-term T cell immune response against tumor associated antigens upon *it*DC immunotherapy using IFN-DC ([@B30], [@B42]).

The Coming of Age of *it*DC: Clinical and Immunological Responses in Recent Trials
----------------------------------------------------------------------------------

While initial attempts of *it*DC showed limited success, recent trials have convincingly shown not only safety and feasibility of *it*DC immunotherapy, but also clear-cut clinical and immunological responses in a high percentage of patients ([Table 1](#T1){ref-type="table"}). In two studies in follicular lymphoma patients, *it*DC in combination with low-dose rituximab alone ([@B30]) or in combination with low-dose rituximab, plus local radiotherapy, and GM-CSF ([@B29]), showed induction of 50 and 36%, respectively, of objective clinical responses in treated and untreated lesions. Notably, in both studies\', induction of both CD8 and CD4 antitumor specific responses were collected and the magnitude of immune activation appeared to correlate with clinical response. Despite several differences between the two trials (type of DC used, pre-conditioning regimen, treatment schedule), these two studies clearly indicate that follicular lymphoma is particularly suited for *it*DC and that this immunotherapy approach is worth being tested in phase II-III clinical trials.

In another interesting clinical study, Lee et al. used CCL21 transduced DC in NSCLC ([@B31]). Despite minimal clinical effects being recorded, induction of T cell responses against tumor associated antigens were observed in 6/16 patients and, in four patients, induction of humoral response was reported. However, more noteworthy is the observation that, with only two DC inoculations, an increase in CD8 T cell infiltration was observed in 56% of patients and that this was correlated with increased expression of checkpoint inhibitors ([@B31]). Similar results were collected by another study using activated DC in several tumor types, showing that increased PD-L1 expression in the majority of patients usually paired by T cell infiltration ([@B35]). Thus, altogether both studies suggest that *it*DC itself increased PD-L1 expression as a result of antigen recognition and CD8 T cell infiltration at the tumor site, clearly pointing to synergies that can result by combining *it*DC and checkpoint blockade.

*it*DC for Checkpoint Blockade Immunotherapy: Arming T Cells While Preparing the Battlefield
--------------------------------------------------------------------------------------------

Checkpoint blockade is revolutionizing cancer therapy with impressive long-term responses in a large variety of tumors. However, the majority of patients still do not benefit from this therapy because of either primary or secondary resistance ([@B87]). Several factors have been identified playing a role behind response to checkpoint blockade: tumor mutation burden ([@B88]), PDL1 expression ([@B89], [@B90]), T cell inflamed microenvironment ([@B91]), T cell repertoire richness and clonality ([@B92]), HLA-I diversity ([@B93]), intestinal microbiota ([@B94], [@B95]), and specific mutations have all been identified as potential markers with prognostic or predictive value in checkpoint blockade therapy ([@B87]). Additionally, cross-priming and CXCL9/10 secretion mediated by intratumoral CD103^+^ BATF3-dependent dendritic cells has also been correlated with response to checkpoint blockade ([@B17], [@B96]). Notably, *it*DC studies have already been shown to lead to increased tumor PDL1 expression and increased T cell responses in several tumor types ([@B31], [@B35]). In our recent study, combining NGS technology with *in silico* prediction, we analyzed T cell responses against patient specific mutations in follicular lymphoma patients before and after *it*DC and observed an increase in pre-existing T cell responses in some patients. This, thus, indicates increased T cell clonality and induction (within the limit of assay detection) of *de novo* T cell response, suggesting increased T cell richness of antigenic repertoire ([@B30]). Altogether, the evidences gained in clinical studies and animal models with *it*DC imply that checkpoint blockade therapy could be enhanced by prior itDC immunotherapy ([Figure 2](#F2){ref-type="fig"}).

![Expected advantages of integrating the "*it*DC" approach in the context of the checkpoint blockade therapy. **(A)** In poorly immunogenic tumors, T cell response is usually low due to multiple checkpoint inhibitors expressed within the tumor microenvironment and immunosuppressive cells. **(B)** Checkpoint blockade therapy may result in increased antitumor T cell response of pre-existing antitumor clones. However, reduced richness and clonality, together with the presence of Treg cell limits checkpoint blockade efficacy, thus resulting in short-lived responses in the majority of patients. **(C)** *it*DC immunotherapy administered prior to checkpoint blockade therapy may lead to increased T cell clonality and richness. In this setting, subsequent checkpoint inhibitor administration is expected to lead to broader antitumor T cell activation. **(D)** *it*DC immunotherapy taking place during checkpoint blockade therapy may boost intratumor T cell activation by secreting IL-12, CXCL9. Additionally, it could overcome inhibitory signals from Treg cells, thus unleashing activation and infiltration of Th1-like CD4^+^ T cells that can further potentiate antitumor T cell response ([@B97]--[@B99]). The figure was made using the Servier Medical ART set by Servier.](fimmu-10-02303-g0002){#F2}

Interestingly, the role of intratumoral DC subsets in response to checkpoint blockade therapy has recently emerged, depicting two independent axis: an NK/cDC1/IL-12-CXCL9 axis needed for effective CD8 T cell response and a Treg/cDC2 axis for effective CD4 T cell response. In one study mainly focused on melanoma, Barry et al. have described the role of intratumoral NK cells in increasing cDC1 abundance within a tumor microenvironment by secreting FLT3LG, showing that the abundance of both populations positively correlates with the response to checkpoint blockade therapy ([@B62]). Further, recent literature has unraveled how intratumoral cDC1 "license" CD8 response during checkpoint blockade by secreting IL-12 and CXCL9, potentiating T cell activation ([@B97], [@B98]). On the other side, Binnewies et al. have discovered that levels of cDC2 populations relative to Treg abundance within tumor microenvironment are responsible of infiltration by CD4 T cells and correlate with the response to checkpoint blockade therapy ([@B99]). Whether *it*DC during checkpoint blockade therapy could potentiate T cell activity by secreting IL-12, CXCL9 or by overcoming inhibitory activity of Treg has not yet been analyzed. However, it is reasonable to expect that activated *it*DC will sum up with intratumoral DC in sustaining T cell responses during checkpoint blockade therapy ([Figure 2](#F2){ref-type="fig"}).

Conclusions and Perspectives {#s3}
============================

The intratumoral delivery of DC has been tested in several different clinical settings, where it has been proved to not only be feasible and safe, but also to be capable of enhancing and/or inducing a tumor-specific immune response.

The possibility to exploit, by an endogenous vaccination strategy, the broad tumor antigen repertoire promptly released by immunogenic tumor pre-conditioning, makes *it*DC a versatile cell therapy, potentially overcoming some of the limitations of therapies based on *ex-vivo* antigen loaded DC, such as the lack of dominant tumor antigens, the availability of tumor samples, and the possible emergence of neo-antigens.

Although the limited number of patients enrolled in phase I studies demands a prudent evaluation of the observed clinical results, data collected so far look promising, and encourages the application of *it*DC to hitherto unexplored clinical settings. More research efforts should yet be devoted to the identification of the optimal DC types to be used in *it*DC strategies, as well as of the most effective strategies for tumor microenvironment pre-conditioning tailored for specific clinical settings. Of note, the accumulating knowledge on their mechanism of action, by showing that *it*DC can affect tumor microenvironment at different levels (including cytokine release and NK cells stimulation), also provides the rationale for their use in combination with immunotherapy approaches currently used in oncology, such as immune checkpoint inhibitors. Based on the evidence available, summarized in this review, we envisage that *it*DC, administered prior or in concomitance with checkpoint inhibitors, by triggering a broader and more effective antitumor immune response, can not only prolong their efficacy, but also provide clinical benefit to patients showing limited responsiveness to checkpoint inhibitors *per se*.
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